The role of erlotinib in EGFR wild-type NSCLC as maintenance therapy was most recently discounted in a phase III trial when erlotinib as maintenance treatment resulted in a median overall survival of 9.7 months compared to a median overall survival of 9.5 months when erlotinib was used on progression [29]. Here, EGFR is linked to non-small cell lung carcinoma.